Hemodynamic Effects of a Standardized Grape Seed Extract Supplementation
Condition(s) studied
Investigational drug(s) / intervention(s)
Standardized Grape Seed Extract: Grape seed dry extract standardized to provide: ≥95.0% of proanthocyanidins by spectrophotometry, ≥5.0% ≤15.0% of catechin and epicatechin by High-Performance Liquid Chromatography (HPLC)
Placebo: Placebo
Study summary
The purpose of this study is to evaluate whether a standardized grape seed extract, compared to placebo, can significantly influence systolic blood pressure (SBP) in individuals with high-normal blood pressure (BP) who are adhering to a low-sodium Mediterranean diet. Additionally, the effects of the grape seed extract on diastolic blood pressure (DBP), other hemodynamic parameters, and the Perceived Stress Score will be assessed.
Eligibility
Primary outcome measure(s)
- Treatment-dependent change in SBP — 8 weeks
The primary objective is to assess and compare the effect on SBP after 8 weeks of treatment with either a standardized grape seed extract or placebo, both administered alongside a low-sodium Mediterranean diet (SOC)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Cardiovascular Internal Medicine Unit, IRCCS University Hospital of Bologna, Bologna, Italy | Bologna | Bo | Recruiting |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07090876 on ClinicalTrials.gov ↗ ← All trials in Italy